Results 221 to 230 of about 29,411 (265)
Some of the next articles are maybe not open access.
Life Sciences, 2020
CD47 (cluster of differentiation 47) is a ubiquitously expressed transmembrane protein that belongs to the immunoglobulin superfamily. CD47 is both a receptor for the matricellular protein thrombospondin-1 (TSP-1) and a ligand for signal-regulatory protein alpha (SIRPα).
Quanli, Cheng +4 more
openaire +2 more sources
CD47 (cluster of differentiation 47) is a ubiquitously expressed transmembrane protein that belongs to the immunoglobulin superfamily. CD47 is both a receptor for the matricellular protein thrombospondin-1 (TSP-1) and a ligand for signal-regulatory protein alpha (SIRPα).
Quanli, Cheng +4 more
openaire +2 more sources
Anti-Cancer Agents in Medicinal Chemistry, 2016
CD47 is a widely expressed cell membrane receptor belonging to the immunoglobulin (Ig) superfamily. CD47 is involved in a number of cellular processes, including proliferation, apoptosis, adhesion and migration through interacting with integrin, thrombospondins and SIRPα. CD47 also plays an important role in the immune system and homeostasis. In recent
Liang, Zhang, He, Huang
openaire +2 more sources
CD47 is a widely expressed cell membrane receptor belonging to the immunoglobulin (Ig) superfamily. CD47 is involved in a number of cellular processes, including proliferation, apoptosis, adhesion and migration through interacting with integrin, thrombospondins and SIRPα. CD47 also plays an important role in the immune system and homeostasis. In recent
Liang, Zhang, He, Huang
openaire +2 more sources
American Journal of Clinical Pathology
Abstract Objectives Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Jingjing Zhang +6 more
openaire +2 more sources
Abstract Objectives Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.
Jingjing Zhang +6 more
openaire +2 more sources
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
Cancer Cell, 2023Juan C Osorio +2 more
exaly
CD47: Beyond an immune checkpoint in cancer treatment
Biochimica Et Biophysica Acta: Reviews on Cancer, 2022Dale Nagle, Wei-Dong Zhang, Xin Luan
exaly